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ABSTRACT
Objective: The purpose of the present investigation was to analyze the effets of zidovudine on the
postimplantation embryo and fetus.
Methods: Pregnant Sprague-Dawley rats were given various doses (10 mg/kg, 30 mg/kg, 150
mg/kg) of zidovudine or saline by an endotracheal tube during the period of embryogenesis (days
6-8, 9-11, 6-11 postconception). The animals were sacrificed on days 18-19 ofpregnancy, and their
fetuses were removed by hysterotomy. Autopsies under low (15) and high (40) power light
microscopy were performed on all fetuses.
Results: There was no statistically significant difference among the groups with respect to mater-
nal weight gain. There were more pregnancy resorptions in the group receiving high-dose zidovu-
dine (150 mg/kg/day) throughout embryogenesis than in the control group (P 0.001, respectively).
Four major structural anomalies were noted among the 689 fetuses examined, but zidovudine was
not associated with an increased frequency ofcongenital anomalies in rats when itwas administered
in doses similar to, 3-, and 15-fold higher than the regimen recommended for adult humans. The
drug, however, was embryocidal in the high-dose group (P 0.002).
Conclusions: These findings are consistent with previous studies of preimplantation mouse em-
bryos that demonstrated an embryocidal effect on preimplantation conceptuses. In summary, post-
implantation embryonic zidovudine exposure was associated with significantly increased pregnancy
losses (resorptions and intrauterine deaths). (C) 1995 Wiley-Liss, Inc.
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formerly called azidothymidine
(AZT), was the first agent commercially avail-
able for the treatment of symptomatic HIV infec-
tion and was shown to be effective.
-3 The current
recommendations from the Centers for Disease
Control (CDC) are that zidovudine therapy be of-
fered to pregnant patients with HIV and near nor-
mal CD4 counts to prevent perinatal transmission
ofHIV.
4
AIDS was previously considered a disease pri-
marily of homosexual men, s but recent seropreva-
lence studies indicate that the male-female ratio
may be much closer to 1:1. Certain inner city ob-
stetric populations have been shown to have sero-
prevalence rates as high as 2%, and nearly 50% of
the sexual partners of HIV-infected IV drug abus-
ers demonstrate serologic evidence of infection. 6’7
Recent reports indicate that the prevalence of HIV
approaches in 250 in the general population, but
the rate among pregnant women is much lower, at
1-2 in 1,000.
Zidovudine acts as an antiviral agent by inhibit-
ing viral reverse transcriptase and by terminating
viral DNA chain elongation.
8 Host cellular DNA
polymerase is also inhibited, but only at concentra-
tions 100 times greater than those required to in-
hibit viral reverse transcriptase in mammals.
9 The
side effects commonly encountered in therapeutic
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trials suggest that in vivo this agent may not be
entirely virus-specific. In one study, 24% of zi-
dovudine recipients developed anemia (hemoglo-
bin <7.5 g/dl), and 16% developed neutropenia
(<500 cells/ram3).
10
Animal studies have also shown rapid placental
transfer of zidovudine,
12 and zidovudine has been
shown to cross the placenta in explanted human
placental cotyledon studies.
13,14 The drug may dis-
rupt early embryonic development because, as men-
tioned previously, the mechanism of action of zi-
dovudine is the inhibition of DNA replication.
Zidovudine was associated with increased preim-
plantation mouse embryo loss in several studies,
15-18 but no congenital abnormalities were detect-
able. The possible mechanism ofembryolethality of
zidovudine was thought to be due to retarded cell
division.
18 Zidovudine is classified by its manufac-
turer as a pregnancy Category C drug. The manu-
facturer quotes a single unpublished study in preg-
nant rats using doses up to 20 times the human dose
that revealed "no evidence of harm to the fetus due
to zidovudine. ’’11 Its use in pregnancy is recom-
mended only if the potential benefits for the mother
justify the potential risks to the embryo or fetus.
Previous investigations suggested that congeni-
tal anomalies may be an effect of exposure to zi-
dovudine during organogenesis. The purpose of
the present study was to test this hypothesis by
administering zidovudine to pregnant rats during
organogenesis.
SUBJECTS AND METHODS
This study was approved by the Institutional Re-
view Board for Animal Research of the University
of Texas Southwestern Medical Center. Virgin fe-
male Sprague-Dawley rats were obtained from a
commercial vendor and allowed to acclimate for 7
days before mating, at which time the females were
placed with males overnight for mating. Vaginal
smears were examined daily and the presence of
spermatozoa on microscopic examination was con-
sidered evidence of pregnancy. The date of the
positive smear was recorded as day zero of preg-
nancy.
The contents of zidovudine capsules were sus-
pended in a sterile water solution with a pH of 8.0.
All animals were dosed by intragastric intubation.
The concentration of zidovudine in the solution was
validated by high-pressure liquid chromatography
in our laboratory using laboratory-assay zidovu-
dine powder provided by the manufacturer (Bur-
roughs Wellcome, Research Triangle Park, NC)
as a standard. All animals were maintained at the
Animal Resource Center of the University ofTexas
Southwestern Medical Center for the duration of
their pregnancies. They had a supply of regular rat
chow and water available ad libitum. The experi-
mental animals were weighed daily but otherwise
had no handling except for the administration of
medication or placebo. The daily doses were ad-
justed according to the daily weights.
Ninety pregnant rats were assigned at random to
one of five groups with 18 per group. The animals
in group I received zidovudine, 10mg/kg/day, in a
single oral morning dose on days 6-11 of preg-
nancy. Those in group II and group III each re-
ceived zidovudine, 30 mg/kg/day, in a single oral
morning dose on days 6-8 and 9-11, respectively;
the pregnant animals in group IV received 150
mg/kg/day of zidovudine orally on days 6-11 post-
conception. The initial experimental design was to
subdivide the high-dose group into days 6-8 and
9-11. The high-dose group was not subdivided
into early (days 6-8) and late (days 9-11) because
no congenital anomalies were noted in the high-
dose group treated throughout the period of em-
bryogenesis. The animals in group V served as
controls and were given an equal volume of sterile
water as a single oral morning dose by intragastric
intubation on days 6-11 of pregnancy. This num-
ber of animals was chosen to comply with the
published recommendations for the design of sub-
primate animal studies.
19 The absorption of zi-
dovudine through intragastric intubation was docu-
mented in a prior investigation conducted in this
laboratory in which the placental transfer was ana-
lyzed.
12
The greatest number ofanatomic structures form
in the rat embryo in the period of gestation from
days 6-11 (taking insemination as day 0). By day
11, the neural structures have formed, somite de-
velopment has occurred, and major organs (includ-
ing heart, kidney, gastrointestinal tract, thyroid
gland, and thymus) and limb buds have developed.
20,21 The low-dose group (group I) received the
adult human dose (10 mg/kg) throughout the ma-
jor period of embryogenesis (days 6-11), while the
medium-dose groups (groups II and III) received
roughly 3 times the adult human dosage (30 mg/
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kg). The medium-dose groups were comprised of
group II, which received the dose early in embryo-
genesis (days 6-8) and group III, which received
the dose later during the period of embryonic de-
velopment (days 9-11). Group IV, the high-dose
group (150 mg/kg/day), receiving 15 times the
usual human therapeutic dose, was treated on days
6-11. The purpose of the high-dose group was to
magnify any teratogenic effect, and the medium-
dose groups were intended to place any effect tem-
porally within the period of embryogenesis.
The animals were sacrificed by decapitation on
days 18-19 of pregnancy (mean, 18.6, SD 0.5)
and the fetuses were immediately harvested by hys-
terectomy. The fetuses were then fixed in 10%
formalin for several weeks. The uteri were exam-
ined immediately for macroscopic evidence of early
pregnancy resorption, and the implantation sites
were counted. Pregnancy resorptions were classi-
fied as implantation sites with no products of con-
ception being recovered. Early intrauterine deaths
were defined as the recovery of products of concep-
tion in a macerated state and the absence of eye
pigmentation. Eye pigmentation is visible by the
14th day postconception,
22 so late intrauterine
deaths were defined as dead fetuses with eye pig-
mentation. None of the recovered dead fetuses had
eye pigment present.
The fetuses were examined under both low (15X)
and high (45X) power microscopy by two trained
observers. They were examined externally for visi-
ble morphologic defects and dissected for gross
examination of defects, as described elsewhere.
22
Particular attention was paid to the thymus, heart
and great vessels, genitourinary organs, adrenal
glands, hard and soft palate, and intracerebral ven-
tricles. The examiners were blinded to the drug
exposure status of the fetuses, i.e., zidovudine-
exposed vs. controls, through a numbered encod-
ing system.
The statistical analysis was performed using ei-
ther chi-squared analysis for comparison between
groups or Fisher exact test, where appropriate. The
analysis of variance was used to compare maternal
weight and the number of offspring between the
control and treatment groups. The Newman-Keuls
multiple-group comparison test was used to estab-
lish which groups were significantly different. The
litter effect was controlled for by an analysis of
covariance, and it was not significant (P > 0.05).
RESULTS
Nonpregnant animals were excluded from the
study. There were 15 pregnancies in groups I and
III, 13 in group II, 17 in group IV, and 14 in
group V (control). There was no significant differ-
ence in maternal weight gain during pregnancy
among the five treatment groups, although the dif-
ference between groups IV and V approached sig-
nificance (P < 0.09). The groups were compared
with regard to litter size (Table 1). The mean litter
size in group IV was 6.7 compared with 11.4 in the
control group (P < 0.01).
All uteri were examined for macroscopic evi-
dence of early pregnancy resorptions. There was
one pregnancy resorption in group I. There were 6
resorptions in group II, 5 in group III, 46 in
group IV, and 2 in group V (control). The differ-
ence between group II and group V (control) ap-
proached statistical significance. The frequency of
pregnancy resorptions in group IV was significantly
higher (P < 0.01) than in any of the groups stud-
ied. Autopsies were performed on all 639 fetuses
(Table 1). The frequency of congenital anomalies
was not different among the groups (P 0.9).
The frequency of congenital anomalies was near to
the expected for the animal species used in this
investigation (1%). The power calculation indi-
cated that an 8-fold increase in the frequency of
congenital anomalies would have been detected in
the present investigation at 80% power. The power
of the current investigation to detect a 2-fold in-
crease in the frequency of congenital anomalies was
40% with ot 0.05.
DISCUSSION
Zidovudine was not associated with an increased
frequency ofcongenital anomalies in Sprague-Daw-
ley rats at the doses give. Group IV (receiving 150
mg/kg/day during embryogenesis) had a greater
number of resorptions than any of the other groups
(P < 0.01). This finding suggests that the medica-
tion may be embryocidal. The embryolethal effect
observed in this study of postimplantation rat em-
bryos is consistent with the deleterious effect previ-
ously demonstrated in preimplantation mouse em-
bryos. s-
It is conceivable that the apparent embryocidal
effect may not have been from embryotoxicity per
se. The agent may have caused such severe early
malformations of major organ systems that the em-
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TABLE I. Pregnancy outcome in zidovudine-treated and control rats
Group no. Litters Implantation Fetuses Resorptions
b
and treatment (no.) sites (no.) No. M SE No.
Intrauterine deaths Anomalies
(%) No. (%) No. (%)
I. Low dose early and late 15 159 158 10.6 1.2 (0.6) 0 0
(I 0 mg/kg)
II. Medium dose early 13 137 120 9.3 1.4 6 (5.0) II (9.2) (0.8)
(30 mg/kg)
III. Medium dose late 15 147 138 9.3 1.2 5 (3.6) 4 (2.9) 2 (I.5)
(30 mg/kg)
IV. High dose early and late 17 167 113 6.7 1.5 46 (40.7) 8 (7.1)
(I 50 mg.kg)
V. Control 14 162 160 11.4 I.I 2 (I.3) 0 0 (0.6)
Totals 74 772 689 9.7 1.3 60 (7.8) 23 (3.0) 4 (0.6)
aNonpregnant animals excluded from this analysis; 18 animals were initially assigned to each group, and number of litters reflects only pregnant animals. The
footnotes explain these exclusions by group.
bDenominator is number of implantation sites.
CDenominator is number of fetuses.
dThree were not pregnant, or preimplantation loss.
eFive were not pregnant, or preimplantation loss.
fAnencephaly.
gOne was not pregnant, or preimplantation loss.
hFour were not pregnant, or preimplantation loss.
iBilateral absence of digits of front limbs.
bryo died and was subsequently resorbed, which
might explain the lack of teratogenic effect noted in
initial reproductive toxicology studies when the
drug was given to pregnant rats at doses up to 20
times the recommended human dose.
11 It is also
possible that no teratogenic effect was seen in this
study because once-daily dosing acutely exposed the
fetuses to relatively small amounts of zidovudine.
However, in a study from our laboratory using
pregnant Long-Evans rats, the agent was concen-
trated in fetal and placental tissues when adminis-
tered as a single oral dose of 30 mg/kg/day. Fetal
and placental zidovudine levels remained elevated
6 h after maternal administration despite a rapid
clearance from the maternal circulation.
1)
Caution must be used in the extrapolation of
findings from animal teratology studies and their
application to the human situation. Of more than
2,000 drugs that have been tested in animal mod-
els, approximately 55% were associated with con-
genital anomalies at high doses. Conversely, there
are only 30-40 known human teratogens. 23’24 Im-
portantly, the sensitivity of animal models for tera-
tology studies is not 100%. Thalidomide, one of
the most highly publicized and tragic human ter-
atogens, shows species-specific teratogenesis and is
25 only a very weak teratogen in rats.
The teratogenicity of zidovudine in humans is
an important issue. Twenty to fifty percent of the
infants of HIV-infected women will contract the
uniformly fatal disease AIDS.
4 Zidovudine has the
ability to decrease the viral antigenemia in vivo and
to inhibit replication and infectivity of the virus in
vitro; it also has a profound effect on the frequency
and severity of neonatal infection. 4’26’27 Zidovu-
dine has no proven teratogenic activity in rats.
However, reliable statements about human terato-
genicity of zidovudine must await studies of the
offspring of nonhuman primates or humans who
were exposed to the drug during early prenatal
development. These results strongly suggest that
zidovudine may be detrimental to early embryonic
development, possibly related to inhibited cell hy-
perplasia. Embryofetal lethality is an indicated risk
of zidovudine therapy during early pregnancy.
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